The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory drug (NSAID) use has increased dramatically in the past two decades. A large proportion of the elderly population (more than 65 years of age) holds a current or recent NSAID prescription, accounting for approximately 90% of all NSAID prescriptions. Despite studies that...

Full description

Bibliographic Details
Main Author: Jerry Tenenbaum
Format: Article
Language:English
Published: Hindawi Limited 1999-01-01
Series:Canadian Journal of Gastroenterology
Online Access:http://dx.doi.org/10.1155/1999/361651
id doaj-9a80b58d916a41799b8254cac02ebda4
record_format Article
spelling doaj-9a80b58d916a41799b8254cac02ebda42020-11-24T23:49:35ZengHindawi LimitedCanadian Journal of Gastroenterology0835-79001999-01-0113211912210.1155/1999/361651The Epidemiology of Nonsteroidal Anti-Inflammatory DrugsJerry Tenenbaum0Department of Medicine, University of Toronto, Toronto, Ontario, CanadaNonsteroidal anti-inflammatory drug (NSAID) use has increased dramatically in the past two decades. A large proportion of the elderly population (more than 65 years of age) holds a current or recent NSAID prescription, accounting for approximately 90% of all NSAID prescriptions. Despite studies that advise finding alternatives for NSAIDs for the management of osteoarthritis, physicians often prescribe NSAIDs first for such common musculoskeletal conditions. Despite being identified as risk factors for gastrointestinal complications, the simultaneous use of two NSAIDs and the coadministration of NSAIDs with corticosteroids and with coumadin continue to occur. The point prevalence of NSAID-induced ulcers is 10% to 30%, and 15% to 35% of all peptic ulcer complications are caused by NSAIDs. The increased risk of gastrointestinal complications when NSAIDs are used is 3% to 5%. This risk increases with other identified risk factors (eg, older age, previous gastrointestinal history, comorbid diseases and poor health). Gastrointestinal causes of hospitalization (eg, gastrointestinal hemorrhage and perforation) and death have increased in parallel to increased NSAID use. ‘Antiulcer’ agents are prescribed twice as often in NSAID users, and the economic impact (eg, diagnostic tests and hospitalization) is that about one-third of the arthritis budget has been dedicated to deal with gastrointestinal side effects of NSAIDs. Misoprostol and omeprazole have been shown to be cytoprotective for the gastroduodenal mucosa when NSAIDs are used, and misoprostol has been shown to reduce the risk of gastroduodenal ulcer complications. Economic evaluations have suggested that these agents are a cost effective means of dealing with such NSAID-associated problems. Although no NSAID is totally safe, a number of studies have demonstrated that NSAIDs may be ranked according to relative gastrointestinal toxicity. The role of Helicobacter pylori in NSAID-associated problems remains uncertain.http://dx.doi.org/10.1155/1999/361651
collection DOAJ
language English
format Article
sources DOAJ
author Jerry Tenenbaum
spellingShingle Jerry Tenenbaum
The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs
Canadian Journal of Gastroenterology
author_facet Jerry Tenenbaum
author_sort Jerry Tenenbaum
title The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs
title_short The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs
title_full The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs
title_fullStr The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs
title_full_unstemmed The Epidemiology of Nonsteroidal Anti-Inflammatory Drugs
title_sort epidemiology of nonsteroidal anti-inflammatory drugs
publisher Hindawi Limited
series Canadian Journal of Gastroenterology
issn 0835-7900
publishDate 1999-01-01
description Nonsteroidal anti-inflammatory drug (NSAID) use has increased dramatically in the past two decades. A large proportion of the elderly population (more than 65 years of age) holds a current or recent NSAID prescription, accounting for approximately 90% of all NSAID prescriptions. Despite studies that advise finding alternatives for NSAIDs for the management of osteoarthritis, physicians often prescribe NSAIDs first for such common musculoskeletal conditions. Despite being identified as risk factors for gastrointestinal complications, the simultaneous use of two NSAIDs and the coadministration of NSAIDs with corticosteroids and with coumadin continue to occur. The point prevalence of NSAID-induced ulcers is 10% to 30%, and 15% to 35% of all peptic ulcer complications are caused by NSAIDs. The increased risk of gastrointestinal complications when NSAIDs are used is 3% to 5%. This risk increases with other identified risk factors (eg, older age, previous gastrointestinal history, comorbid diseases and poor health). Gastrointestinal causes of hospitalization (eg, gastrointestinal hemorrhage and perforation) and death have increased in parallel to increased NSAID use. ‘Antiulcer’ agents are prescribed twice as often in NSAID users, and the economic impact (eg, diagnostic tests and hospitalization) is that about one-third of the arthritis budget has been dedicated to deal with gastrointestinal side effects of NSAIDs. Misoprostol and omeprazole have been shown to be cytoprotective for the gastroduodenal mucosa when NSAIDs are used, and misoprostol has been shown to reduce the risk of gastroduodenal ulcer complications. Economic evaluations have suggested that these agents are a cost effective means of dealing with such NSAID-associated problems. Although no NSAID is totally safe, a number of studies have demonstrated that NSAIDs may be ranked according to relative gastrointestinal toxicity. The role of Helicobacter pylori in NSAID-associated problems remains uncertain.
url http://dx.doi.org/10.1155/1999/361651
work_keys_str_mv AT jerrytenenbaum theepidemiologyofnonsteroidalantiinflammatorydrugs
AT jerrytenenbaum epidemiologyofnonsteroidalantiinflammatorydrugs
_version_ 1725481730691825664